# US 2006/0154243 A1 · Antigenic peptides of SARS coronavirus and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154243 A1
- Document ID: US20060154243A1
- Status: Published application
- Kind: A1
- Application number: 11/337,226
- Filed: 2006-01-20
- Published: 2006-07-13
- Earliest claimed: 2003-07-21
- Inventors: Jan Ter Meulen; Jaap Goudsmit; Peter Timmerman; Jelle Slootstra
- Web page: https://patentgrep.com/patent/US20060154243A1

## CPC

- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 39/12: Viral antigens
- C07K 14/005: from viruses
- G01N 33/56983: {Viruses}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/505: {comprising antibodies}
- C07K 2319/00: Fusion polypeptide
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention pertains to antigenic peptides of SARS-CoV and their use in diagnostic test methods and in the treatment of condition resulting from SARS-CoV. Furthermore, this invention provides antibodies capable of specifically recognizing the peptides of the invention. The antibodies can also advantageously be used in diagnostic test methods and in the treatment of conditions resulting from SARS-CoV.

## Claims

### Claim 1

An isolated peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:11-SEQ ID NO:80 and SEQ ID NO:81.

### Claim 2 (depends on 1)

A second peptide, wherein said second peptide consists of at least two peptides of claim 1.

### Claim 3 (depends on 1)

A part of the peptide of claim 1, wherein the part is recognized by antibodies present in serum derived from a subject that has been immunized against Severe Acute Respiratory Syndrome Coronavirus (SARS-Co-V).

### Claim 4 (depends on 1)

An analogue of the peptide of claim 1, wherein said analogue has an amino acid sequence consisting of the amino acid sequence of the peptide with one or more amino acid substitutions in the peptide, and said analogue is recognized by antibodies present in serum derived from a subject that has been immunized with Severe Acute Respiratory Syndrome Coronavirus (SARS-Co-V).

### Claim 5 (depends on 1)

A fusion protein or a conjugate comprising the isolated peptide of claim 1.

### Claim 6 (depends on 1)

An isolated nucleic acid molecule encoding the peptide of claim 1.

### Claim 7 (depends on 1)

An isolated antibody, wherein said antibody is able to specifically recognize the peptide claim 1.

### Claim 8 (depends on 7)

The isolated antibody of claim 7, wherein said antibody is a monoclonal antibody.

### Claim 9 (depends on 8)

The isolated antibody of claim 8, wherein said monoclonal antibody is a human monoclonal antibody.

### Claim 10 (depends on 7)

The isolated antibody of claim 7, wherein the antibody has Severe Acute Respiratory Syndrome Coronavirus (SARS-Co-V) neutralizing activity.

### Claim 11 (depends on 7)

An isolated nucleic acid molecule encoding the antibody of claim 7.

### Claim 12 (depends on 6)

A vector comprising at least one nucleic acid molecule of claim 6.

### Claim 13 (depends on 12)

A host comprising at least one vector of claim 12.

### Claim 14 (depends on 13)

The host of claim 13, wherein the host is a cell.

### Claim 15 (depends on 1)

A medicament for the detection, prevention and/or treatment of a condition in a subject resulting from a Severe Acute Respiratory Syndrome Coronavirus (SARS-Co-V), wherein said medicament comprises the peptide of claim 1.

### Claim 16 (depends on 1)

An immunogen for the detection, prevention and/or treatment of a condition in a subject resulting from a Severe Acute Respiratory Syndrome Coronavirus (SARS-Co-V), wherein said immunogen comprises the isolated peptide of claim 1.

### Claim 17 (depends on 1)

A vaccine comprising the isolated peptide of claim 1.

### Claim 18 (depends on 7)

A medicament for the detection, prevention and/or treatment of a condition in a subject resulting from a Severe Acute Respiratory Syndrome Coronavirus (SARS-Co-V), wherein said medicament comprises the isolated antibody of claim 7.

### Claim 19

(canceled)

### Claim 20 (depends on 1)

A diagnostic test method for determining the presence of antibodies recognizing Severe Acute Respiratory Syndrome Coronavirus (SARS-Co-V) in a sample, said method comprising the steps of:
contacting said sample with the isolated peptide of claim 1 and
determining whether antibodies in said sample bind to said peptide.

### Claim 21 (depends on 7)

A diagnostic test method for determining the presence of a binding molecule of SARS-CoV in a sample, said method comprising the steps of:
contacting said sample with the isolated antibody of claim 7 and
determining whether the antibody binds to the binding molecule of SARS-CoV in said sample.

### Claim 22 (depends on 20)

The diagnostic test method of claim 20, wherein the sample is a sample from a human subject potentially infected with a Severe Acute Respiratory Syndrome Coronavirus (SARS-Co-V).

### Claim 23 (depends on 1)

An isolated polypeptide, said isolated polypeptide comprising at least one of the peptides of claim 1.

### Claim 24 (depends on 23)

The isolated polypeptide of claim 23, wherein the isolated polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-SEQ ID NO:9 and SEQ ID NO:10.

### Claim 25 (depends on 5)

A nucleic acid molecule encoding the fusion protein or conjugate of claim 5.

### Claim 26 (depends on 5)

An antibody, wherein said antibody is able to specifically recognize the fusion protein or conjugate of claim 5.

### Claim 27 (depends on 11)

A vector comprising at least one nucleic acid molecule of claim 11.

### Claim 28 (depends on 27)

A host comprising at least one vector of claim 27.

### Claim 29 (depends on 5)

A medicament for detection, prevention and/or treatment of a condition in a subject resulting from a Severe Acute Respiratory Syndrome Coronavirus (SARS-Co-V), wherein said medicament comprises the fusion protein or conjugate of claim 5.

### Claim 30 (depends on 11)

A medicament for detection, prevention and/or treatment of a condition in a subject resulting from a Severe Acute Respiratory Syndrome Coronavirus (SARS-Co-V), wherein said medicament comprises the isolated nucleic acid molecule of claim 11.

### Claim 31 (depends on 5)

An immunogen for detection, prevention and/or treatment of a condition in a subject resulting from a Severe Acute Respiratory Syndrome Coronavirus (SARS-Co-V), wherein said immunogen comprises a fusion protein or conjugate of claim 5.

### Claim 32 (depends on 11)

An immunogen for detection, prevention and/or treatment of a condition in a subject resulting from a Severe Acute Respiratory Syndrome Coronavirus (SARS-Co-V), wherein said immunogen comprises the isolated nucleic acid molecule of claim 11.

### Claim 33 (depends on 11)

A composition for the detection, prevention and/or treatment of a condition in a subject resulting from a Severe Acute Respiratory Syndrome Coronavirus (SARS-Co-V), wherein said composition comprises the isolated nucleic acid molecule of claim 11.

### Claim 34 (depends on 5)

A composition for the detection, prevention and/or treatment of a condition in a subject resulting from a Severe Acute Respiratory Syndrome Coronavirus (SARS-Co-V), wherein said composition comprises the fusion protein or conjugate of claim 5.

### Claim 35 (depends on 27)

A composition for the detection, prevention and/or treatment of a condition in a subject resulting from a Severe Acute Respiratory Syndrome Coronavirus (SARS-Co-V), wherein said composition comprises the vector of claim 27.

### Claim 36 (depends on 5)

A diagnostic test method for determining the presence of antibodies recognizing Severe Acute Respiratory Syndrome Coronavirus (SARS-Co-V) in a sample, said method comprising the steps of:
contacting said sample with the fusion protein or conjugate of claim 5 and
determining whether antibodies in said sample bind to said fusion protein or conjugate.

### Claim 37 (depends on 21)

The diagnostic test method of claims 21, wherein the sample is a sample from a human subject believed to be infected with a Severe Acute Respiratory Syndrome Coronavirus (SARS-Co-V).
